Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of August 2023, specifically dated August 8, 2023. The document serves as a report of a foreign private issuer regarding a corporate governance event rather than a financial performance report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document contains no financial statements or operational metrics.
Material Changes
There are no material financial changes reported in this filing. The primary event is the adjournment of the Annual General Meeting of Shareholders originally scheduled for August 8, 2023, due to a lack of the required legal quorum.
Outlook and Management Commentary
Management has announced that the Annual General Meeting of Shareholders will reconvene on August 9, 2023, at 3:00 p.m. Israel time at the Company's office. The filing incorporates by reference various Registration Statements on Form S-8 and Form F-3 filed between 2013 and 2023.
Key Facts for Investor Verification
- The Annual General Meeting scheduled for August 8, 2023, was adjourned due to insufficient quorum.
- The meeting is rescheduled for August 9, 2023, at 3:00 p.m. Israel time.
- No financial data or operational updates are included in this specific filing.
- The filing is signed by Dror Ben-Asher, Chief Executive Officer.